



PATENT

Case Docket No. SAEG143.002AUS

Date: March 29, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : TAMAKI, et al.
Appl. No. : 10/748,490
Filed : December 30, 2003
For : AGENT FOR PREVENTION
AND TREATMENT OF
INFLAMMATORY BOWEL
DISEASE
Examiner : Unknown
Group Art Unit : Unknown

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 29, 2004

(Date)

Katsuhiro Arai, Reg. No. 43,315

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with fourteen (14) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Katsuhiro Arai
Registration No. 43,315
Agent of Record
Customer No. 20,995
(949) 760-0404

**INFORMATION DISCLOSURE STATEMENT**

Applicant : TAMAKI, et al.
App. No. : 10/748,490
Filed : December 30, 2003
For : AGENT FOR PREVENTION AND
TREATMENT OF INFLAMMATORY
BOWEL DISEASE
Examiner : Unknown
Group Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing 14 references that are also enclosed.

This Information Disclosure Statement is being filed with an RCE or within three months of the filing date of this application and no fee is required in accordance with 37 C.F.R. § 1.97(b)(1), (b)(2), or (b)(4).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 29, 2004

By: 
Katsuhiro Arai
Registration No. 43,315
Agent of Record
Customer No. 20,995
(949) 760-0404

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
SAEG143.002AUSAPPLICATION NO.
10/748,490INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
TAMAKI, et al.FILING DATE
December 30, 2003GROUP
Unknown

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	Claudio Fiocchi, "Inflammatory Bowel Disease: Etiology and Pathogenesis," Gastroenterology; 115, pp. 182-205 published in 1998
	2	Tagaya, et al., "ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin; possible involvement of dithiol-reduction in the IL-2 receptor induction," The EMBO Journal Vol. 8, No. 3 pp. 757-764 published in 1989
	3	Powis, et al., "PROPERTIES AND BIOLOGICAL ACTIVITIES OF THIOREDOXINS," Annual Reviews in Biophysics and Biomolecular Structure: 30 pp. 421-455 published in 2001
	4	Lih-Brody, et al., "Increased Oxidative Stress and Decreased Antioxidant Defenses in Mucosa of Inflammatory Bowel Disease," Digestive Diseases and Science, Vol. 41, No. 10 pp. 2078-2086 published in 1996
	5	McKenzie, et al., "Evidence of Oxidant-induced Injury to Epithelial Cells during Inflammatory Bowel Disease," Journal Clinical Investigation Vol. 98, pp. 136-141 published in 1996
	6	Korenaga, et al., "Impaired Antioxidant Defense System of Colonic Tissue and Cancer Development in Dextran Sulfate Sodium-Induced Colitis in Mice," Journal of Surgical Research 102, pp. 144-149 published in 2002
	7	Okayasu, et al., "A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice," Gastroenterology; 98 pp. 694-702 published in 1990
	8	Ohkawara, et al., "Amelioration of Dextran Sulfate Sodium-Induced Colitis by Anti-macrophage Migration Inhibitory Factor Antibody in Mice," Gastroenterology; 123 pp. 256-270 published in 2002
	9	Jeffers, et al., "A Novel Human Fibroblast Growth Factor Treats Experimental Intestinal Inflammation," Gastroenterology; 123. pp. 1151-1162 published in 2002
	10	Williams, et al., "Enhanced Survival and Mucosal Repair After Dextran Sodium Sulfate-Induced Colitis in Transgenic Mice That Overexpress Growth Hormone," Gastroenterology; 120 pp. 925-937 published in 2001
	11	Kruidenier, et al., "Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease - radicals or ridiculous?" Alimentant Pharmacology & Therapeutics; 16 pp. 1997-2015 published in 2002
	12	Nakamura, et al., "Circulating thioredoxin suppresses lipopolysaccharide-induced neutrophil chemotaxis," Proceedings of the National Academy of Science of the United States of America Vol. 98, No. 26 pp. 15143-15148 published in December 18, 2001
	13	Nakamura, et al., "Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS," Proceedings of the National Academy of Science of the United States of America Vol. 98, No. 5 pp. 2688-2693 published in February 27, 2001
	14	Powis, et al., "Properties and Biological Activities of Thioredoxins," Annual Reviews of Pharmacology and Toxicology 41 pp. 216-295 published in 2001

H:\DOCS\KOA\KOA-2083.DOC
032604

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	